Advertisement

Topics

Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market

09:00 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Independent new company will accelerate development of Illumina’s forensic genomics technologies to enable more insight than traditional methods Illumina, Inc. (NASDAQ: ILMN) today announced plans with Telegraph Hill ...

Other Sources for this Article

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
ir@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com

NEXT ARTICLE

More From BioPortfolio on "Illumina and Telegraph Hill Partners Launch Verogen, Inc. to Drive Adoption of Next-Generation Sequencing in the Global Forensic Genomics Market"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...